Pathophysiology of coronary vascular remodeling: Relationship with traditional risk factors for coronary artery disease

Cardiology in Review

Volumn 22, Issue 1, 2014, Pages 13-16

  Pant, Rojina ^a   Marok, Rajinder ^a   Klein, Lloyd W ^a  

^a ADVOCATE ILLINOIS MASONIC MEDICAL CENTER   (United States)

Author keywords

cardiovascular risk factors; endothelial dysfunction; matrix metalloproteinase; vascular remodeling

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ARHALOFENATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RIOCIGUAT; ROSIGLITAZONE;

ACUTE CORONARY SYNDROME; AGE; AGING; ARTERY CALCIFICATION; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORRELATIONAL STUDY; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY HISTORY; GENDER; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR MECHANICS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SMOKING; THROMBOCYTE ACTIVATION; VASCULAR REMODELING;

CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LIPOPROTEINS; MATRIX METALLOPROTEINASES; OXIDATIVE STRESS; PLATELET ACTIVATION; RISK FACTORS; SMOKING;

EID: 84890555782     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31829dea90     Document Type: Review

References (40)

1. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375
2. Weissman NJ. Vascular remodeling: Do we really need yet another study? J Am Coll Cardiol. 2003;42:811-813
3. Losordo DW, Rosenfield K, Kaufman J, et al. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation. 1994;89:2570-2577
4. White AJ, Duffy SJ, Walton AS, et al. Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease. Cardiovasc Res. 2007;75:813-820
5. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res. 2002;90:251-262
6. Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: An intravascular ultrasound study. Circulation. 2000;101:598-603
7. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381
8. Jormsjö S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase- 12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 2000;86:998-1003
9. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820
10. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420
11. Spinetti G, Kraenkel N, Emanueli C, et al. Diabetes and vessel wall remodelling: From mechanistic insights to regenerative therapies. Cardiovasc Res. 2008;78:265-273
12. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 Pt 2):581-587
13. Stapleton PA, Goodwill AG, James ME, et al. Hypercholesterolemia and microvascular dysfunction: Interventional strategies. J Inflamm (Lond). 2010;7:54
14. Keaney JF Jr, Guo Y, Cunningham D, et al. Vascular incorporation of alphatocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest. 1996;98:386-394
15. Mehta A, Yang B, Khan S, et al. Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endotheliumdependent relaxation. Role of P-selectin. Arterioscler Thromb Vasc Biol. 1995;15:2076-2083
16. Ward MR, Pasterkamp G, Yeung AC, et al. Arterial remodeling. Mechanisms and clinical implications. Circulation. 2000;102:1186-1191
17. Yoneyama S, Arakawa K, Yonemura A, et al. Oxidized low-density lipoprotein and high-density lipoprotein cholesterol modulate coronary arterial remodeling: An intravascular ultrasound study. Clin Cardiol. 2003;26:31-35
18. Taylor AJ, Burke AP, Farb A, et al. Arterial remodeling in the left coronary system: The role of high-density lipoprotein cholesterol. J Am Coll Cardiol. 1999;34:760-767
19. Hamasaki S, Higano ST, Suwaidi JA, et al. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. Arterioscler Thromb Vasc Biol. 2000;20:737-743
20. Klein LW . Cigarette smoking, atherosclerosis and the coronary hemodynamic response: A unifying hypothesis. J Am Coll Cardiol. 1984;4:972-974
21. Perlstein TS, Lee RT. Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol. 2006;26:250-256
22. Schächinger V, Britten MB, Elsner M, et al. A positive family history of premature coronary artery disease is associated with impaired endotheliumdependent coronary blood flow regulation. Circulation. 1999;100:1502-1508
23. Caulin-Glaser T, García-Cardeña G, Sarrel P, et al. 17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res. 1997;81:885-892
24. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation. 2002;105:939-943
25. Burke AP, Kolodgie FD, Farb A, et al. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 2002;105:297-303
26. Nicholls SJ, Tuzcu EM, Wolski K, et al. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol. 2007;49:263-270
27. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: Pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044-1059
28. Demer LL. A skeleton in the atherosclerosis closet. Circulation. 1995;92:2029-2032
29. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2004;286:H742-H748
30. Polikandriotis JA, Mazzella LJ, Rupnow HL, et al. Peroxisome proliferatoractivated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-Activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol. 2005;25:1810-1816
31. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684
32. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol. 2005;45:1925-1931
33. Magri CJ, Gatt N, Xuereb RG, et al. Peroxisome proliferator-Activated receptor-γ and the endothelium: Implications in cardiovascular disease. Expert Rev Cardiovasc Ther. 2011;9:1279-1294
34. Fryer LG, Hajduch E, Rencurel F, et al. Activation of glucose transport by AMP-Activated protein kinase via stimulation of nitric oxide synthase. Diabetes. 2000;49:1978-1985
35. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35(1 Pt 2):501-506
36. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: Evidence for an L-Arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071
37. Verhaar MC, Honing ML, van Dam T, et al. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc Res. 1999;42:752-760
38. Fleissner F, Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal. 2011;15:933-948
39. Hassona MD, Elnakish MT, Abouelnaga ZA, et al. The effect of selective antihypertensive drugs on the vascular remodeling-Associated hypertension: Insights from a profilin1 transgenic mouse model. J Cardiovasc Pharmacol. 2011;57:550-558
40. McLaughlin VV. Looking to the future: A new decade of pulmonary arterial hypertension therapy. Eur Respir Rev. 2011;20:262-269